TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Lake Street Capital

Lake Street Capital assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock.

Several other research firms have also recently weighed in on TLSI. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm reiterated a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Finally, Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI opened at $5.53 on Thursday. The stock has a 50 day moving average price of $4.79 and a 200 day moving average price of $4.74. The stock has a market capitalization of $168.63 million, a PE ratio of -2.22 and a beta of 0.51. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 4,826 shares of TriSalus Life Sciences stock in a transaction dated Monday, January 27th. The stock was bought at an average price of $5.42 per share, with a total value of $26,156.92. Following the completion of the transaction, the chief executive officer now owns 429,503 shares in the company, valued at $2,327,906.26. The trade was a 1.14 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James Emmett Young purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were acquired at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the transaction, the chief financial officer now owns 30,000 shares of the company’s stock, valued at $169,500. This trade represents a 25.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 124,868 shares of company stock valued at $575,843 in the last three months. 32.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after buying an additional 3,710 shares during the period. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $184,000. Vestcor Inc bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $108,000. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $92,000. Finally, Walleye Capital LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth $66,000. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.